Cargando…

Quantity of Immune Cells Predict Response to Immunotherapy in Cancer

Detalles Bibliográficos
Autores principales:	Salgado, Roberto, Gevaert, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554484/ https://www.ncbi.nlm.nih.gov/pubmed/34746724 http://dx.doi.org/10.1016/j.eclinm.2021.101170

Ejemplares similares

Medical education in Malaysia: quality versus quantity
por: Wong, Rebecca S. Y., et al.
Publicado: (2017)

Cancer environmental immunotherapy: starving tumor cell to death by targeting TGFB on immune cell
por: Huang, Xing, et al.
Publicado: (2021)

Neoantigens in cancer immunotherapy: quantity vs. quality
por: Wolf, Yochai, et al.
Publicado: (2023)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Assessing the quantity of pulmonary edema in critically ill children
por: McAuley, Daniel F, et al.
Publicado: (2010)

Targetless T cells in cancer immunotherapy
por: thor Straten, Per, et al.
Publicado: (2016)

Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges
por: Xing, Shuqin, et al.
Publicado: (2022)

Strategies to sensitize cancer cells to immunotherapy
por: George, Andrew, et al.
Publicado: (2021)

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
por: Masucci, Giuseppe V., et al.
Publicado: (2017)

Quality Versus Quantity: Using Scholarly Activity to Assess Otolaryngology Residency Candidates
por: Carlson, Kristy J., et al.
Publicado: (2023)

Kinetics reshape antitumor immunity: Timing, duration, and combination are of importance for successful cancer immunotherapy
por: Jin, Seung Mo, et al.
Publicado: (2023)

Cancer immunotherapy by immunosuppression
por: Prehn, Richmond T, et al.
Publicado: (2010)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy
por: Linch, Stefanie N., et al.
Publicado: (2016)

Engineering autoreactive T and B cell responses toward active immunotherapy for inflammatory diseases
por: Chang, Jason Y. H., et al.
Publicado: (2021)

DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy
por: De Smet, Charles
Publicado: (2023)

Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity
por: Tang, Tianyu, et al.
Publicado: (2022)

Defining the critical hurdles in cancer immunotherapy
por: Fox, Bernard A, et al.
Publicado: (2011)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

How to select cancer patients for immunotherapy
por: Pfeiffer, Per, et al.
Publicado: (2021)

Cancer immunotherapy: avoiding the road to perdition
por: Chiriva-Internati, Maurizio, et al.
Publicado: (2004)

Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023)

Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis
por: Zhai, Wen-Yu, et al.
Publicado: (2022)

Immunoactivating the tumor microenvironment enhances immunotherapy as predicted by integrative computational model
por: Popel, Aleksander S.
Publicado: (2020)

Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
por: Bell, R. Bryan, et al.
Publicado: (2022)

Bispecific antibodies come to the aid of cancer immunotherapy
por: Amelio, Ivano, et al.
Publicado: (2021)

HSP70-based anti-cancer immunotherapy
por: Guzhova, Irina V., et al.
Publicado: (2016)

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
por: Visconti, Roberta, et al.
Publicado: (2017)

Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer
por: Parikh, Mamta, et al.
Publicado: (2022)

3D modelling of γδ T‐cell immunotherapy
por: Hull, Caroline M., et al.
Publicado: (2022)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Biological and Molecular Factors Predicting Response to Adoptive Cell Therapies in Cancer
por: Ferrer, Gerardo, et al.
Publicado: (2022)

Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned
por: Bible, Keith C.
Publicado: (2021)

Immunological barriers to immunotherapy in primary and metastatic breast cancer
por: De Martino, Mara, et al.
Publicado: (2021)

Circulating protein and antibody biomarker for personalized cancer immunotherapy
por: Yuan, Jianda
Publicado: (2016)

TCR diversity – a universal cancer immunotherapy biomarker?
por: McNeel, Douglas G.
Publicado: (2016)

CXCR3: Here to stay to enhance cancer immunotherapy?
por: Rogava, Meri, et al.
Publicado: (2019)

COVID-19: the use of immunotherapy in metastatic lung cancer
por: Davis, Alexander P, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jam88e8ahoujmkutarkiqfb0e6